Sanj K Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), filed a Statement of Changes in Beneficial Ownership on September 3, 2026, reporting transactions dated September 1, 2026, including the vesting of restricted share units, a share disposition, and new equity grants.
Key Highlights
- RSU vesting: Four separate RSU tranches totaling 31,318 Class A Ordinary Shares vested on September 1, 2026, and were acquired indirectly through The Patel Family Irrevocable Trust of 2025.
- Share disposition: 15,144 Class A Ordinary Shares were disposed of on September 1, 2026, at $79.28 per share, indirectly through The Patel Family Irrevocable Trust of 2025 (transaction code F).
- New RSU grant: 30,050 restricted share units were granted on September 1, 2026, vesting 25% annually over four years beginning September 1, 2026, held directly.
- New share option grant: 120,150 share options were granted with an exercise price of $79.28, expiring August 31, 2036, held directly.
- Indirect holdings across trusts: Following the reported transactions, indirect holdings include 92,348 shares in The Patel Family Irrevocable Trust of 2025, 109,795 shares in The Marina 2016 Irrevocable Trust, and 51,794 shares in The Anglia 2013 Revocable Trust.
- Remaining RSUs: After vesting transactions, Patel holds 25,826, 12,475, and 6,481 RSUs directly from prior-year grants, plus the newly granted 30,050 RSUs.
Kiniksa Chairman and CEO Transaction Details: RSU Vesting, Disposition, and New Equity Awards
According to the filing, Sanj K Patel, who serves as Chairman and CEO of Kiniksa Pharmaceuticals International, plc, reported a series of transactions on September 1, 2026. Four RSU tranches vested on that date, each representing a contingent right to receive one Class A Ordinary Share. These vested tranches originated from grants made on September 1, 2022 (9,991 shares), September 1, 2023 (6,481 shares), September 1, 2024 (6,237 shares), and September 1, 2025 (8,609 shares), all held indirectly through The Patel Family Irrevocable Trust of 2025. Each original grant was structured to vest 25% on each yearly anniversary of the grant date over a four-year period.
The filing also discloses a disposition of 15,144 Class A Ordinary Shares at $79.28 per share (transaction code F), reducing the trust's holdings to 92,348 shares following the reported transactions. On the same date, Patel received a new grant of 30,050 RSUs and 120,150 share options, both held directly. The new RSUs vest 25% annually beginning September 1, 2026, while the options vest 25% on the first anniversary of the September 1, 2026 vesting commencement date and in 36 equal monthly installments thereafter, with an expiration date of August 31, 2036, according to the filing.
The filing further reports that indirect beneficial ownership is spread across three separate trusts: The Patel Family Irrevocable Trust of 2025 (92,348 shares), The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016 (109,795 shares), and The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 (51,794 shares). The form was signed by Douglas Barry as Attorney-in-Fact on September 3, 2026.
What Was Disclosed
The filing covers RSU vesting and a share disposition by Kiniksa's Chairman and CEO through an irrevocable trust, alongside new RSU and share option grants made on September 1, 2026, with indirect holdings reported across three separate trusts.




Please wait processing your request...